diff --git a/archive-covid-19/18 May, 2023.html b/archive-covid-19/18 May, 2023.html new file mode 100644 index 0000000..ceea669 --- /dev/null +++ b/archive-covid-19/18 May, 2023.html @@ -0,0 +1,184 @@ + +
+ + + ++Background: The origin of divergent SARS-CoV-2 spike sequences found in wastewater, but not in clinical surveillance, remains unclear. These cryptic wastewater sequences have harbored many of the same mutations that later emerged in Omicron lineages. We first detected a cryptic lineage in municipal wastewater in Wisconsin in January 2022. Named the Wisconsin Lineage, we sought to determine the geographic origin of this virus and characterize its persistence and evolution over time. Methods: We systematically sampled maintenance holes to trace the origin of the Wisconsin Lineage. We sequenced spike RBD domains, and where possible, whole viral genomes, to characterize the evolution of this lineage over the 13 consecutive months that it was detectable. Findings: The persistence of the Wisconsin Lineage signal allowed us to trace it from a central wastewater plant to a single facility, with a high concentration of viral RNA. The viral sequences contained a combination of fixed nucleotide substitutions characteristic of Pango lineage B.1.234, which circulated in Wisconsin at low levels from October 2020 to February 2021, while mutations in the spike gene resembled those subsequently found in Omicron variants. Interpretation: We propose that prolonged detection of the Wisconsin Lineage in wastewater represents persistent shedding of SARS-CoV-2 from an infected individual, with ongoing within-host viral evolution leading to an ancestral B.1.234 virus accumulating Omicron-like mutations. Funding: The Rockefeller Foundation, Wisconsin Department of Health Services, Centers for Disease Control and Prevention (CDC), National Institute on Drug Abuse (NIDA), and the Center for Research on Influenza Pathogenesis and Transmission. +
++Background: The COVID-19 pandemic is unceasingly spreading across the globe, and recently a highly transmissible Omicron SARS-CoV-2 variant (B.1.1.529) has been discovered in South Africa and Botswana. Rapid identification of this variant is essential for pandemic assessment and containment. However, variant identification is mainly being performed using expensive and time-consuming genomic sequencing. Methods and results: In this study we propose an alternative RT-qPCR approach for the detection of the Omicron BA.1 variant using a low-cost and rapid SYBR Green method. We have designed specific primers to confirm the deletion mutations in the spike (S ∆143-145) and the nucleocapsid (N ∆31-33) which are characteristics of this variant. For the evaluation, we used 120 clinical samples from patients with PCR-confirmed SARS-CoV-2 infections, and displaying an S-gene target failure (SGTF) when using TaqPath COVID-19 kit (Thermo Fisher Scientific, Waltham, USA) that included the ORF1ab, S, and N gene targets. Our results showed that all the 120 samples harbored S ∆143-145 and N ∆31-33, which was further confirmed by Whole genome sequencing (WGS) of 4 samples thereby validating our SYBR Green-based protocol. Conclusions: This protocol can be easily implemented to rapidly confirm the diagnosis of the Omicron BA.1 variant in COVID-19 patients and prevent its spread among populations, especially in countries with high prevalence of SGTF profile. +
++To respond to pandemics such as COVID-19, policy makers have relied on interventions that target specific population groups or activities. Because targeting is operationally challenging and contentious, rigorously quantifying its benefits and designing practically implementable policies that achieve some of these benefits is critical for effective and equitable pandemic control. We propose a flexible framework that leverages publicly available data and a novel optimization algorithm based on model predictive control and trust region methods to compute optimized interventions that can target two dimensions of heterogeneity: age groups and the specific activities that individuals normally engage in. We showcase a complete implementation focused on the Ile-de-France region of France and use this case study to quantify the benefits of dual targeting and to propose practically implementable policies. We find that dual targeting can lead to Pareto improvements, reducing the number of deaths and the economic losses. Additionally, dual targeting allows maintaining higher activity levels for most age groups and, importantly, for those groups that are most confined, thus leading to confinements that are arguably more equitable. We then fit decision trees to explain the decisions and gains of dual-targeted policies and find that they prioritize confinements intuitively, by allowing increased activity levels for group-activity pairs with high marginal economic value prorated by social contacts, which generates important complementarities. Because dual targeting can face significant implementation challenges, we introduce two practical proposals inspired by real-world interventions - based on curfews and recommendations - that achieve a significant portion of the benefits without explicitly discriminating based on age. +
++Background The effectiveness of COVID-19 monoclonal antibody and antiviral therapies against severe COVID-19 outcomes is unclear. Initial benefit was shown in unvaccinated patients and before the Omicron variant emerged. We used the OpenSAFELY platform to emulate target trials to estimate the effectiveness of sotrovimab or molnupiravir, versus no treatment. Methods With the approval of NHS England, we derived population-based cohorts of non-hospitalised high-risk individuals in England testing positive for SARS-CoV-2 during periods of dominance of the BA.1 (16/12/2021-10/02/2022) and BA.2 (11/02/2022-21/05/2022) Omicron sublineages. We used the clone-censor-weight approach to estimate the effect of treatment with sotrovimab or molnupiravir initiated within 5 days after positive test versus no treatment. Hazard ratios (HR) for COVID-19 hospitalisation or death within 28 days were estimated using weighted Cox models. Results Of the 35,856 [BA.1 period] and 39,192 [BA.2 period] patients, 1,830 [BA.1] and 1,242 [BA.2] were treated with molnupiravir and 2,244 [BA.1] and 4,164 [BA.2] with sotrovimab. The estimated HRs for molnupiravir versus untreated were 1.00 (95%CI: 0.81;1.22) [BA.1] and 1.22 (0.96;1.56) [BA.2]; corresponding HRs for sotrovimab versus untreated were 0.76 (0.66;0.89) [BA.1] and 0.92 (0.79;1.06) [BA.2]. Interpretation Compared with no treatment, sotrovimab was associated with reduced risk of adverse outcomes after COVID-19 in the BA.1 period, but there was weaker evidence of benefit in the BA2 period. Molnupiravir was not associated with reduced risk in either period. +
++Objective: To determine the associated factors with mortality, in addition to age and sex, in a high-complexity hospital in Bogota, Colombia, during the first year of the pandemic. Design: A case-control study. Setting: High-complexity center above 2,640 meters above sea level (masl) in Colombia. Methods: A case-control study was conducted on 564 patients admitted to the hospital with confirmed COVID-19. Deceased patients (n: 282) and a control group (n: 282), matched by age, sex, and month of admission, were included. Clinical and paraclinical variables were retrospectively obtained by systematic revision of clinical records. Multiple imputations by chained equation (MICE) were implemented to account for missing variables. Classification and regression trees (CART) were estimated to evaluate the interaction of associated factors on admission and their role in predicting mortality during hospitalization. Results: Most of the patients included were males in the seventh decade of life. Most of the admissions occurred between July and August 2021. Surprisingly, recovered patients reported heterogeneous symptomatology, whereas deceased patients were most likely to present respiratory distress, dyspnea, and seizures on admission. In addition, the latter group exhibited a higher burden of comorbidities and alterations in laboratory parameters. After the imputation of datasets, CART analysis estimated 14 clinical profiles based on respiratory distress, LDH, dyspnea, hemoglobin, D-dimer, ferritin, blood urea nitrogen, C-reactive protein, PaO2/FiO2, dysgeusia, total bilirubin, platelets, and gastroesophageal reflux disease. The accuracy model for prediction was 85.6% (P < 0.0001). Conclusion: Multivariate analysis yielded a reliable model to predict mortality in COVID-19. This analysis revealed new interactions between clinical and paraclinical features in addition to age and sex. Furthermore, this predictive model could offer new clues for the personalized management of this condition in clinical settings. Keywords: SARS-CoV-2, COVID-19, Mortality, Predictors, Risk Factors +
++COVID-19 has infected humans worldwide, causing millions of deaths or prolonged symptoms in survivors. The transient or persistent symptoms after SARS-CoV-2 infection have been defined as post-COVID-19 conditions (PCC). We conducted a study of 151 Brazilian PCC patients to analyze symptoms and immunoglobulin profiles, taking into account gender, vaccination, hospitalization and age. Fatigue and myalgia were the most common symptoms and lack of vaccination, hospitalization, and neuropsychiatric and metabolic comorbidities were relevant for the development of PCC. Analysis of serological immunoglobulins showed that IgA was higher in PCC patients, especially in the adult and elderly groups. Also, non-hospitalized and hospitalized PCC patients produced high and similar levels of IgA. Our results indicated that the detection of IgA antibodies against SARS-CoV-2 during the course of the disease could be associated with the development of PCC and may be an immunological signature to predict prolonged symptoms in COVID-19 patients. +
+The Standard of Care Combined With Glucocorticoid in Elderly People With Mild or Moderate COVID-19 - Condition: COVID-19
Intervention: Drug: Glucocorticoid
Sponsor: Huashan Hospital
Not yet recruiting
Conducting Clinical Trials of the Medicine “Rutan Tablets 0.1g” No. 10 in the Complex Therapy of COVID-19 - Condition: Patients With COVID-19
Interventions: Drug: The drug “Rutan 0.1”.; Other: Basic treatment
Sponsor: Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan
Completed
Arginine Replacement Therapy in COVID-19 - Condition: COVID-19
Intervention: Drug: Arginine Hydrochloride
Sponsor: Emory University
Not yet recruiting
Effectiveness of a Second COVID-19 Vaccine Booster in Chinese Adults - Condition: COVID-19
Interventions: Biological: Intramuscularly administered Ad5-nCoV vaccine; Biological: Aerosolized Ad5-nCoV; Biological: DelNS1-2019-nCoV-RBD-OPT1; Biological: SYS6006
Sponsor: Jiangsu Province Centers for Disease Control and Prevention
Not yet recruiting
Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, ARVI - Condition: COVID-19 Respiratory Infection
Interventions: Drug: Rutan 25 mg; Other: Control group
Sponsor: Research Institute of Virology, Ministry of Health of the Republic of Uzbekistan
Completed
A Pilot Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment - Condition: Post COVID-19 Cognitive Impairment
Interventions: Device: Vielight Neuro RX Gamma active device; Device: Vielight Neuro RX Gamma sham device
Sponsor: Vielight Inc.
Not yet recruiting
PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway - Conditions: Post COVID-19 Condition, Unspecified; SARS-CoV2 Infection; COVID-19
Interventions: Drug: Nirmatrelvir/ritonavir; Drug: Placebo
Sponsors: Haukeland University Hospital; University of Bergen
Not yet recruiting
Use of a Hypochlorous Acid Spray Solution in the Treatment of COVID-19 Patients : COVICONTROL Study . - Condition: SARS CoV 2 Infection
Interventions: Other: Spray with Hypochlorous Acid Group; Other: Spray with Placebo Group
Sponsor: University of Monastir
Recruiting
Role of Vit-D Supplementation on BioNTech, Pfizer Vaccine Side Effect and Immunoglobulin G Response - Condition: COVID-19 Respiratory Infection
Intervention: Combination Product: Vitamin-D
Sponsor: Sulaimany Polytechnic university
Completed
REVERSE-Long COVID-19 With Baricitinib Pilot Study - Condition: Post-Acute COVID-19 Syndrome
Intervention: Drug: Baricitinib 4 MG
Sponsors: Vanderbilt University Medical Center; Emory University; University of California, San Francisco; University of Minnesota; Vanderbilt University; Yale University
Not yet recruiting
Safety, Tolerability and Immunogenicity of Alveavax-v1.2, a BA.2/Omicron-optimized, DNA Vaccine for COVID-19 Prevention - Condition: Sars-CoV-2 Infection
Interventions: Drug: Alveavax-v1.2; Drug: Janssen Ad26.COV2.S
Sponsor: Alvea Holdings, LLC
Completed
Post Covid-19 Dysautonomia Rehabilitation Randomized Controlled Trial - Conditions: Post-Acute COVID-19 Syndrome; Dysautonomia
Interventions: Procedure: Rehabilitation; Procedure: Standard of Care
Sponsors: Evangelismos Hospital; National and Kapodistrian University of Athens; LONG COVID GREECE; 414 Military Hospital of Special Diseases
Recruiting
Exercise for Health in Patients With Post-acute Sequelae of COVID-19 - Condition: Long COVID
Intervention: Other: Rehabilitation program
Sponsors: Campus docent Sant Joan de Déu-Universitat de Barcelona; Hospital de Mataró; University of Barcelona
Active, not recruiting
Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome. - Condition: Post-COVID Syndrome
Interventions: Behavioral: RehabCovid_Telematic; Behavioral: RehabCovid_ImmersiveVR; Behavioral: Control_Condition
Sponsors: Consorci Sanitari de Terrassa; University of Barcelona; Universitat de Girona; Unitat Assistencial i Preventiva de l’Esport- Centre d’Alt rendiment; Politecnic University of Catalonia; Corporación Fisiogestión
Recruiting
RADx-UP- Impact of Community Health Worker Deployment - Conditions: Diabetes; COVID-19; Community Health Workers; Health Behavior; Health Knowledge, Attitudes, Practice
Intervention: Behavioral: Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake
Sponsor: Morehouse School of Medicine
Active, not recruiting
In silico design of miniprotein to inhibit SARS-CoV-2 variant Omicron spike protein - Omicron is a novel variant of SARS-CoV-2 that is currently spreading globally as the dominant strain. The virus first enters the host cell through the receptor binding domain (RBD) of the spike protein by interacting with the angiotensin-converting enzyme 2 (ACE2). Thus, the RBD protein is an ideal target for the design of drugs against the Omicron variant. Here, we designed several miniprotein inhibitors in silico to combat the SARS-CoV-2 Omicron variant using single- and double-point mutation…
Conformal Hydrogel-Skin Coating on a Microfluidic Channel through Microstamping Transfer of the Masking Layer - Poly(dimethylsiloxane) (PDMS) is used in microfluidics owing to its biocompatibility and simple fabrication. However, its intrinsic hydrophobicity and biofouling inhibit its microfluidic applications. Conformal hydrogel-skin coating for PDMS microchannels, involving the microstamping transfer of the masking layer, is reported herein. A selective uniform hydrogel layer with a thickness of ∼1 μm was coated in diverse PDMS microchannels with a resolution of ∼3 μm, maintaining its structure and…
The C-terminal 32-mer fragment of hemoglobin alpha is an amyloidogenic peptide with antimicrobial properties - Antimicrobial peptides (AMPs) are major components of the innate immune defense. Accumulating evidence suggests that the antibacterial activity of many AMPs is dependent on the formation of amyloid-like fibrils. To identify novel fibril forming AMPs, we generated a spleen-derived peptide library and screened it for the presence of amyloidogenic peptides. This approach led to the identification of a C-terminal 32-mer fragment of alpha-hemoglobin, termed HBA(111-142). The non-fibrillar peptide has…
Challenges and Progress in Designing Broad-Spectrum Vaccines Against Rapidly Mutating Viruses - Viruses evolve to evade prior immunity, causing significant disease burden. Vaccine effectiveness deteriorates as pathogens mutate, requiring redesign. This is a problem that has grown worse due to population increase, global travel, and farming practices. Thus, there is significant interest in developing broad-spectrum vaccines that mitigate disease severity and ideally inhibit disease transmission without requiring frequent updates. Even in cases where vaccines against rapidly mutating…
Flavonoid as possible therapeutic targets against COVID-19: a scoping review of in silico studies - CONCLUSION: These studies allow us to provide a basis for in vitro and in vivo assays to assist in developing drugs for the treatment and prevention of COVID-19.
Discovery of dual S-RBD/NRP1-targeting peptides: structure-based virtual screening, synthesis, biological evaluation, and molecular dynamics simulation studies - Both receptor-binding domain in spike protein (S-RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and human neuropilin-1 (NRP1) are important in the virus entry, and their concomitant inhibition may become a potential strategy against the SARS-CoV-2 infection. Herein, five novel dual S-RBD/NRP1-targeting peptides with nanomolar binding affinities were identified by structure-based virtual screening. Particularly, RN-4 was found to be the most promising peptide targeting S-RBD…
Compounds from myrtle flowers as antibacterial agents and SARS-CoV-2 inhibitors: In-vitro and molecular docking studies - Plants and their related phytochemicals play a key role in the treatment of bacterial and viral infections, which inspire scientists to design and develop more efficient drugs starting from the phytochemical active scaffold. This work aims to characterize the chemical compounds of Myrtus communis essential oil (EO) from Algeria and to evaluate its in vitro antibacterial effect, as well as the in silico anti-SARS-CoV-2 activity. The chemical profile of hydrodistilled EO from myrtle flowers was…
Declined Humoral Immunity of Kidney Transplant Recipients to SARS-CoV-2 Vaccines - CONCLUSION: KTRs’ humoral response after SARS-CoV-2 vaccination is dramatically inhibited and wanes. Antibody levels show a significant decline over time in KTRs with hypertension; receiving triple immunosuppressive therapy or steroid-based or antimetabolite-based regimens; receiving mixed mRNA and viral vector vaccines; and with a transplant of >10 years.
Interactive network pharmacology and electrochemical analysis reveals electron transport-mediating characteristics of Chinese medicine formula Jing Guan Fang - BACKGROUND: Jing Guan Fang (JGF) is an anti-COVID-19 Chinese Medicine decoction comprised of five medicinal herbs to possess anti-inflammatory and antiviral properties for treatment. This study aims to electrochemically decipher the anti-coronavirus activity of JGF and show that microbial fuel cells may serve as a platform for screening efficacious herbal medicines and providing scientific bases for the mechanism of action (MOA) of TCMs.
Physicochemical characterization of reusable facemasks and theoretical adhesion by a challenged bacterium - CONCLUSION: Such information is valuable to understand attachment of biological particles and to contribute in the inhibition of this attachment.
Screening of SARS-CoV-2 antivirals through a cell-based RNA-dependent RNA polymerase (RdRp) reporter assay - COVID-19 (Coronavirus Disease 2019) caused by SARS-CoV-2 (Severe Acute Respiratory Syndrome CoronaVirus-2) continues to pose an international public health threat and thus far, has resulted in greater than 6.4 million deaths worldwide. Vaccines are critical tools to limit COVID-19 spread, but antiviral drug development is an ongoing global priority due to fast-spreading COVID-19 variants that may elude vaccine efficacies. The RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 is an essential…
SARS-CoV-2 Omicron sub-lineages differentially modulate interferon response in human lung epithelial cells - Although most of the attention was focused on the characterization of changes in the Spike protein among variants of SARS-CoV-2 virus, mutations outside the Spike region are likely to contribute to virus pathogenesis, virus adaptation and escape to the immune system. Phylogenetic analysis of SARS-CoV-2 Omicron strains reveals that several virus sub-lineages could be distinguished, from BA.1 up to BA.5. Regarding BA.1, BA.2 and BA.5, several mutations concern viral proteins with antagonistic…
Purification and characterisation of heparin-like sulfated polysaccharides with potent anti-SARS-CoV-2 activity from snail mucus of Achatina fulica - Heparin-like sulfated polysaccharide, acharan sulfate, was purified from the mucus of an African giant snail with unique sulfated glycosaminoglycans (GAGs). This study reported on finding novel and safe heparin resources from Achatina fulica for further use as well as easy isolation and purification of the active fraction from the initial raw material. Its structure was characterised by a strong-anion exchange combined with high-performance liquid chromatography (HPLC) and nuclear magnetic…
Structure-guided optimization of adenosine mimetics as selective and potent inhibitors of coronavirus nsp14 N7-methyltransferases - The COVID-19 pandemic reveals the urgent need to develop new therapeutics targeting the SARS-CoV-2 replication machinery. The first antiviral drugs were nucleoside analogues targeting RdRp and protease inhibitors active on nsp5 Mpro. In addition to these common antiviral targets, SARS-CoV-2 codes for the highly conserved protein nsp14 harbouring N7-methyltransferase (MTase) activity. Nsp14 is involved in cap N7-methylation of viral RNA and its inhibition impairs viral RNA translation and immune…
Immunization with Recombinant Accessory Protein-Deficient SARS-CoV-2 Protects against Lethal Challenge and Viral Transmission - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a worldwide coronavirus disease 2019 (COVID-19) pandemic. Despite the high efficacy of the authorized vaccines, there may be uncertain and unknown side effects or disadvantages associated with current vaccination approaches. Live-attenuated vaccines (LAVs) have been shown to elicit robust and long-term protection by the induction of host innate and adaptive immune responses. In this study, we sought to verify an attenuation…
Don’t Believe Donald Trump: A Failure to Raise the Debt Ceiling Would Be Disastrous - The ex-President’s intervention has made a fraught situation even more complicated. - link
The Vanishing Acts of Vladimir Putin - One of the seeming paradoxes of the Russian President is the degree to which he is at once a unitary micromanager and an absent, aloof, and often indecisive leader. - link
The Salmon in the Sky - A painted plane that flew the Alaskan coast. - link
The Fight for the Soul of a School Board - In a small Missouri town, a campaign to remove literature from the high-school library forced members of the community to reckon with the meaning of “parents’ rights.” - link
The Black Families Seeking Reparations in California’s Gold Country - Descendants of enslaved people want land seized by the state returned and recognition of the gold rush’s rich, and largely ignored, Black history. - link
+From non-competes to non-disparagement agreements, your employer has plenty of ways to lock you down even after you leave. +
++You’d think that when a job is over, it’s over. You quit or you’re fired or laid off and then that’s that. Except that’s not always what happens. A lot of the time, even after you’ve cut ties, your former employer maintains some control over what you can say or do. It’s like a toxic ex you can’t warn anyone about because they might sue you, and who gets a say in who you go out with next. +
++It’s true that at the current moment, swaths of workers are more in the driver’s seat than they have been in years, thanks to a hot labor market that’s driven wages up, provided some people mobility, and given workers more leverage against their employers. But work hasn’t changed as much as some more optimistic headlines might suggest, and many of the fundamental power dynamics remain. +
++When you take on a new job, it’s often still a my-way-or-the-highway situation with your employer, and not just while you’re working your 9 to 5. Once you leave, companies have mechanisms such as non-compete clauses and non-disparagement agreements that make your post-work life a little bit harder. Much of the time, they don’t enforce those mechanisms, but the threat that they might gives them power. +
+ ++I recently spoke with Peter Shamshiri, a former employment lawyer, about all the ways your boss keeps control of you even if they’re no longer your boss. Shamshiri is a host of two podcasts, If Books Could Kill, about airport bestsellers, and 5-4, about the Supreme Court. The latter podcast, 5-4, lost him his job last year when the higher-ups found out he was on it (he’d previously been anonymous). Our conversation, edited for length and clarity, is below. +
++It feels like when your company fires you or you quit, they should really not be able to have any more control over what you do. But that’s not the case, right? +
++There are a couple of ways that companies can maintain contractual control over you after your employment ends. One is that you sign something during your employment that applies to your post-employment period. So you will sign a document that delineates all these obligations you have as an employee, and some of them implicitly or explicitly stretch beyond the termination of your employment. +
++The other one is you agree when you part with the company to certain terms that include restrictive covenants — so non-competes, trade secret agreements, non-solicitation, things like that. In exchange for severance, for example, you’d be agreeing to that stuff. It’s still the company leveraging their position to get you to agree to restrictive covenants after you’re done with them. +
++So if Vox axes me tomorrow, which I hope they don’t, there are probably definitely rules somewhere about what I can say about them or whatever? +
++Most likely, you have at some point signed something saying that you will agree to certain levels of confidentiality with respect to their proprietary information, their trade secrets. It’s quite possible that that agreement also extends to you going to a competitor within a set period of time or you soliciting Vox employees once you are at a competitor, for example. +
++A lot of large companies will, essentially, when someone is onboarded, hand them a piece of paper and say, “Hey, to come work here, you need to sign this.” And it has all of these terms, and some of them will stretch beyond their employment, which could literally be years, decades in the future at the time of signing. People sign because it’s a prerequisite for maintaining the job. +
++Whenever I start a new job, I think, “Oh, I should look through this,” and then it’s like, “What am I going to do? Say no?” Is it possible to negotiate? +
++You may be able to negotiate yourself out of certain restrictive covenants if you are of particular import or the company is a little bit smaller. But if you’re at a large enough company, they’re not going to set the precedent of individually negotiating with people on this stuff. They’re just going to say, “Sign it or turn down the job.” +
++To get into specifics, let’s talk noncompetes a little. Those are the clauses that say an employee can’t work for a competitor. I feel like a lot of people have come across them when looking for a job, or you hear the horror stories of, like, restaurants using them. How are they even allowed? +
++Well, they’re not allowed everywhere, and I’ll get to that in a second. +
++The purpose of them generally is to try to protect company secrets. When you’re an employee, the company is trusting you with their proprietary and confidential information, and if you go over to a competitor, all of a sudden, the competitor has access to this stuff. Now, what’s odd about that is most companies will have you already agree to maintain confidentiality, to maintain the secrecy of their trade secrets. So the noncompete is substantively duplicative of that. The reason companies use that is because if someone goes to a competitor, it’s hard to figure out if they’ve spilled the beans on company secrets. So the easy solution is just to prevent them from going to the competitor altogether. +
++Almost all jurisdictions have restrictions on these. They need to be limited in duration, meaning maybe six or 12 months after you leave, but not beyond that. They need to be limited in their geographic scope. A lot of companies limit them by industry or even specifically name competitors that you can’t go to. Under California labor laws, you cannot use noncompetes. The FTC has proposed a rule to ban them. They say that the cost to employees is something like $300 billion a year. +
++The restaurant industry is a great example of how and where these can be abused, because it’s just the Wild West out there. I don’t think that any judge in most jurisdictions would hold up a noncompete in the restaurant industry, but no one’s going to lawyer up over a restaurant job and try to figure that out. So, they’re just being used as intimidation, essentially. +
++Years ago I had a friend who basically didn’t take a job because of a noncompete. The fear was like, well what happens if it doesn’t work out? You can never work in your area for the next year? +
++That’s what’s so bizarre about it. Say you have a career in selling life insurance, and they tell you in your contract you can’t go over to a competitor. What exactly are you supposed to do? You’re being blocked out of the only industry where you have expertise. They’ll often say it’s only within a 100-mile radius. But what does that tell you? You can’t work at a company in the industry that you’re familiar with, in the city that you live in, or anywhere nearby. If you want to move across the country, then you can do it, or if you totally want to switch careers, you’re good. +
++It doesn’t make sense, and that’s why there’s been a push to limit these, to outlaw them altogether. The legitimate uses of this are like 5 percent of the reason that companies use them. They are used to intimidate employees, to keep employees in their roles and make them nervous about where they go next. Frankly, they prevent other companies from coming over and hiring too many folks so that you have legal leverage when companies try to do that. +
++In finance, isn’t it the case that sometimes employers will pay you to not do anything for six months or something? You get “garden leave.” +
++Garden leaves are relatively rare. In certain industries where the pay is high, employees have a little more leverage in general, so they can say, fine, I’m at JPMorgan, I won’t go over to Goldman, but I want my six months of pay right then. If you’re serving tables, then you’re on your own. Essentially, noncompetes are more effective the more financially unstable someone is. +
++Are noncompetes even enforced though? +
++Almost never. It’s a conversation that will occasionally happen when higher-level folks may come from one company to another between legal departments, but these things go to court once in a blue moon. +
++It’s a bluff that employees can often call, but a) you need to know that, and b) you’re still running a risk. If a company feels like dragging you into court over this, at the very least, it’s going to make you miserable. +
++What about nondisclosure agreements, the contracts that say what people can’t say about their employers or former employers? +
++I would say that NDAs are a little bit distinct. I wouldn’t put them in the same bucket as most of these post-employment restrictive covenants — trade secret protections; noncompetes; non-solicitations, meaning you can’t solicit colleagues to come join you at a new company; non-disparagement agreements, meaning you can’t say anything disparaging about the company; and non-interference provisions, which means you can’t go try to intercept your old company’s clients. +
++NDAs tend to be limited to specific circumstances. So if you’re a lawyer or a finance person, you’ll often sign NDAs when you’re on a confidential deal. The controversial use of NDAs is: Okay, hey, you were harassed during your time at our company, we will compensate you in some way and in exchange you sign this NDA so we don’t have a PR problem here. We’ve seen more restrictions around that recently, especially in the sexual harassment context. That’s not something that would generally be part of your post-employment suite of obligations by default. It’s usually circumstantial. +
++What about non-disparagement agreements? Like, people have to promise not to say anything bad, even though they’ve got plenty of bad things to say? +
++Non-disparagement has got to be the most bizarre of the post-employment restrictive covenants, and they’ll often apply during employment too. +
++“I won’t say anything mean at the company,” at a certain high level, if you’re an employee, might make some sense. If you’re a Vox employee and you go on Twitter and say, “You know, I think Vox sucks, just like, substantively, I think the coverage is awful.” I think what the company would say was, well, do we really have to allow our employees to say that the product is awful, for example? On the other side of that, is there literally anyone who doesn’t violate this? Maybe I’m hanging out with a cynical crowd, but I don’t know anyone who has never said something a little bit disparaging about their employer. +
++The way that these operate is that because their scope is so broad, if you get laid off, for example, and vent about it on social media, which is a relatively human experience and human reaction, all of a sudden, your company can claim that you violated non-disparagement. If part of your severance package is non-disparagement, what they’re saying is, “We don’t want to hear about this on social media.” And your ability to criticize your employer, even in ways that are substantively true, is limited. +
++What’s different about defamation is that what you say has to be false for it to be defamation. If you say something true, that’s not defamation. People can accurately relay what happened to them at a company, and if the company says that that’s disparaging, that that would hurt their reputation, you still violated the non-disparagement clause, even though you didn’t tell a lie. +
++So if I lose my job tomorrow and go to Twitter and say “this person doesn’t do their job” or something, and that’s true, would the repercussions be that the company takes away my severance? Can they sue me? +
++If we’re talking about a severance agreement you violated, the agreement itself would tell you what the damages are. At the very least, they would try to seek an injunction telling you to stop, that’s pretty minimal. Most of them have outlined monetary damages — say either you’re going to pay back the severance or you’re going to pay back some set amount of damages. +
++It depends on the contract, but companies have a lot of options available to them. Generally speaking, and I’m being very general here because there are different cultures, it’s rare, even with a violation, to see someone go after an already-paid severance just because the PR can be so brutal. But they maintain that right, and that’s the whole point — all the risk is in the employee’s court. They are chilling the ability of the employee to speak confidently and freely about their experience. +
++Can I sue my employer? What is a forced arbitration clause? +
++That’s basically saying that if there’s a dispute about your employment, we’re going to arbitrate it, we’re not going to go to court. Arbitration is much more favorable to employers — they win more frequently, the costs are lower, it just sucks for employees. But that’s another thing that’s frequently buried in your employment contract — you’re signing away your ability to sue in court. Though I think “woke” employers have moved away from this in the last couple of years. +
++What if someone’s employer, say, committed a crime? With Theranos, some employees knew there was a problem and were afraid to speak out because of NDAs and non-disparagement agreements, right? +
++Technically, there are carve-outs — most agreements say you have the right to report things to certain government agencies, etc. But Theranos is a good example of how an aggressive legal team can make that irrelevant. You had employees being like, “Hey, this seems like maybe it’s fraud,” and you had some of the best lawyers in the country coming down on them with threats of litigation. Even if you’re technically, legally in the right, the whole point of these is for the company to maintain leverage to squeeze you if they want to. +
++In most situations, if the company is violating the law, you are legally allowed to talk about that and to escalate that to regulators. But is being legally in the right going to save you when you have David Boies knocking on your door and pointing to your NDA and threatening litigation? +
++So I guess the big overarching question here is, why are we like this? Or rather, why are companies allowed to behave like this? You quit or you’re laid off or fired, and they still have all this control even though you basically have no relationship anymore? +
++We are a country and a society that worships contracts as a method of doing business. This is something that, a century ago, the Supreme Court was holding up as a foundational element of our society, during the Lochner era, where they were upholding all these brutal labor practices and saying we should allow people to contract to whatever they want. That era is over to some degree — labor regulations kicked in in the ’20s and ’30s and exist to some degree to this day, but I think the worship of contract is what brings us here. The idea that someone can’t agree to something on their own terms, even if the leverage and the power dynamics are completely out of whack, Americans have a hard time with that. That’s why stuff like this is so prolific. +
++There’s also a real argument that much of this is anti-competitive. These restrictions are preventing market forces from maximizing their efficiency to some degree, right? You can’t go over to another employer, you can’t hire away your former colleague, you can’t try to convince our clients that they should come follow you to the new company. All of these things are anti-competitive, they’re not in the spirit of market capitalism, and yet they are extremely common. +
++Like if I want to steal all of your clients and I’m better than you, maybe I should be able to. +
++Right. If you have a pitch to the client to come join you, why exactly shouldn’t that be allowed? It’s hard to make the argument from the broader economic perspective. +
++We live in a world that’s constantly trying to sucker us and trick us, where we’re always surrounded by scams big and small. It can feel impossible to navigate. Every two weeks, join Emily Stewart to look at all the little ways our economic systems control and manipulate the average person. Welcome to The Big Squeeze. +
++Sign up to get this column in your inbox. +
++Have ideas for a future column or thoughts on this one? Email emily.stewart@vox.com. +
+This painful, mosquito-borne virus could spread even more if new innovations can’t scale. +
++Break-bone fever. Break heart fever. Seven-day fever. They are all names for the painful — often debilitating and sometimes deadly — mosquito-borne disease called dengue fever. +
++Dengue can cause high fever, nausea, rash, body aches, and stiff movements, and can leave patients suffering from depression and fatigue in its wake. +
++Dengue has been around since at least the 17th century, but cases of the infection skyrocketed in the last two decades — from only a little over 505,000 cases in 2000, to 5.2 million cases in 2019. Today, half the world’s population — who live in areas where Dengue-carrying mosquitoes are prevalent — is at risk of the illness. While dengue is already endemic in 100 countries, new regions are reporting cases of the virus every year, thanks to travel, trade, urbanization, and climate change expanding the range of the mosquitoes that transmit dengue. +
++In March, Sudan, a country currently embroiled in a civil war, experienced its widest outbreak of the disease and detected dengue fever for the first time on record in its capital city of Khartoum. At the same time, Argentina reported “elevated” dengue fever activity across the country. +
++While dengue fever isn’t as deadly as other mosquito-borne viruses — such as Japanese Encephalitis, a dengue-related virus found in southern and eastern Asia — large outbreaks can quickly overwhelm health care systems, worsening the toll of other illnesses and medical problems. “It’s one of those rare diseases that impact families, impacts communities, and impacts the country-level health systems,” said Derek Wallace, a physician who is the dengue vaccine program lead for the pharmaceutical company Takeda. +
++But even as the threat of dengue grows, new developments over the past decade — including a recently approved vaccine and an initiative to infect mosquitos with a virus-resistant bacteria — could mean that dengue eradication is on the horizon. +
++“I think one of the terrible things about dengue, if you live in an endemic transmission area, is you can’t really protect against it,” said Scott O’Neill, founder and CEO of the World Mosquito Program, a nonprofit aiming to eliminate mosquito-borne illnesses. “When you live in a situation where you can’t control your exposure, that can be quite a frightening thing, and many people live with a lot of fear around diseases like dengue and Zika, and what it could do to their children or to their family.” +
++Dengue fever and many other vector-borne viruses — including chikungunya, Zika fever, and yellow fever — are usually transmitted via the bite of the tropical Aedes mosquito. This mosquito prefers to live near and feed on humans, and can easily pass these viruses from an infected individual to others in the population. In the case of dengue fever, mosquitos are the vector — the living organisms that can spread infectious pathogens between humans — but other common disease-spreading vectors are ticks, flies, and fleas. +
++And since dengue fever symptoms normally do not appear until four to 10 days after infection, people often go about their normal life, going outside, and exposing themselves to mosquitos. When a mosquito bites an infected individual, it will then carry that virus and pass it on to other people via its bite. +
++“Sometimes people actually have asymptomatic disease. They don’t even know that they had dengue,” said Ashley St. John, an associate professor at Duke-NUS Medical School who researches vector-borne pathogens like dengue. “That’s a major way it spreads is through people who don’t realize that they’re infected still going about their daily routine, and being in an environment where mosquitoes can continue to transmit the virus.” +
++Unlike other vectors, the Aedes mosquito thrives in urban environments since it can breed in very small quantities of water, such as the water pooled in a leaf, said St. John. As more people live in urban areas, the risk the Aedes mosquitos pose — given their ability to thrive in populous communities— grows. +
++“Another aspect that goes hand-in-hand with it is really human mobility,” said St. John. “Overall, we’re traveling a lot more than we used to. Travelers are a major group who are at risk for exposure to dengue when they arrive in some of these dengue-endemic regions.” When a traveler is exposed to dengue in an endemic region, they risk bringing the disease back to their community. +
++Dengue fever causes a range of mild to severe symptoms, but one of the most concerning is plasma leakage, or when fluid leaves the blood vessels and enters the lungs or abdomen. This deadly condition occurs in only a small portion of the annual half a million dengue-related hospitalizations, but treatment for the problem — IV fluids — is not foolproof, said Wallace. If too much IV fluid is given to a patient, it can drown the lungs and send them into respiratory distress. This life-or-death balancing act often plays out over an approximately seven-hour period following an infected individual’s fever breaking. +
++The primary reason scientists and researchers struggled to make progress on dengue prevention and treatment methods is because there are four different serotypes — or variations — of the virus that cause dengue fever. That essentially means that dengue fever behaves like four different viruses. +
++When someone is infected with one of the four dengue serotypes, they develop antibodies that help them beat the infection and protect them against future infections of the same serotype. But, unlike many illnesses, dengue’s serotypes are so different that the antibodies that protect against one serotype of the virus may not protect against the other three, said St. John. +
++Sounds a little bit like another virus circulating around: Covid. Between omicron, delta, and beta, Covid had many different variants, and genetic diversity, said David Martinez, a co-author of a 2020 study on the diversity within dengue serotype genomes and an assistant professor of immunobiology at the Yale School of Medicine. “Vast genetic diversity is certainly out there for many different viral families. So this is not unique to dengue,” he said. “But within the flaviviruses [vector-borne RNA viruses] that can infect humans and are actually a major problem in human populations, then dengue does seem to be a bit more unique in that regard.” +
++There is still no treatment to counter the dengue virus itself, and there is no universally available prevention method. +
++Instead, the World Health Organization (WHO) recommends that infected individuals rest, hydrate, and take over-the-counter pain relievers — treatments that can address symptoms. To prevent infection, WHO suggests avoiding mosquito bites by wearing full-coverage clothing, sleeping with insect-repellent-treated nets, and installing window screens. +
++But no one can stay indoors or under a mosquito net forever — which is why researchers have for decades been working on an effective dengue vaccine. +
++In 2015, Mexico approved the first dengue vaccine, Sanofi Pasteur’s Dengvaxia. At first, health experts welcomed the shot, given it was the only available medical prevention measure, but, two years later, after at least 11 countries approved it, concerns began to arise around its safety for those who had never been infected with dengue before. +
++In most types of viral infections, antibodies protect someone from developing severe disease. But dengue can act differently, essentially “hitching a ride” on antibodies and using them to enter and infect healthy cells, said Martinez. That’s why a strong immune response — where antibodies are produced — is not always beneficial, and instead can increase the risk of severe disease. +
++An analysis by Sanofi, WHO, and partnered researchers of long-term data showed that individuals who were never infected — seronegative people — were more likely to develop a severe reaction to a first-time infection if they received the Dengvaxia vaccine. The shot contains a live, weakened virus that teaches a recipient’s body to produce antibodies, which is also similar to how the chickenpox and measles vaccines work. (Dengvaxia uses a genetically engineered yellow fever virus to create this response.) But some researchers believe that because antibodies can help dengue infect cells instead of fight the virus, first-time dengue infections after the vaccines become more similar to reinfections, which are more likely to be severe. +
++In response, Sanofi updated its guidance for the shot in 2017, recommending the vaccine only be given to those with a confirmed prior dengue infection, or seropositive people. But the damage was already done — in the Philippines, where the vaccine was rolled out as part of a national campaign, parental confidence in vaccines plummeted, from 82 percent in 2015 to 21 percent in 2018. +
++Aside from the Dengvaxia vaccine (which is still approved in over a dozen countries, including the US, for those with a laboratory-confirmed prior dengue infection), there are approximately five other dengue vaccines in development as of 2018. The Japanese pharma company Takeda’s vaccine, TAK-003, is showing promising results. It’s a live-attenuated vaccine like Dengvaxia’s shot, but rather than using the yellow fever virus as its backbone, it uses the dengue serotype 2 virus. Takeda’s series of shots have been approved in Indonesia, Argentina, and Brazil for both seropositive and seronegative people, and the US Food and Drug Administration has granted the shot priority review. +
++One reason for the vaccine’s seeming success is that the Takeda team distinguished between seropositive and seronegative individuals in its trials (to ensure the vaccine was effective and safe for both populations), said Wallace, who is leading Takeda’s dengue vaccine development. “From a vaccine perspective, what we don’t want to do is be priming somebody for a worse infection later,” said Wallace. “We don’t want the vaccine to be acting like a primary infection, meaning the first real natural exposure to dengue is worse than it would otherwise have been.” +
++To ensure this safety, the trial took baseline blood samples from 20,000 children across eight countries, Wallace said. Additionally, the team collected data over four and a half years on the efficacy of the vaccine. This data showed that the vaccine prevented 84 percent of hospitalized dengue cases and 61 percent of symptomatic dengue cases. +
++In the last two decades researchers have made tremendous progress in dengue-vaccine development, but the nature of the virus means it’s likely a single immunization alone will not stop the disease. +
++A vaccine that uses only one serotype to protect against dengue fever may not create a balanced immune response, said St. John. Over time, immunity to the four different serotypes diminishes at different rates, making an individual more susceptible to certain serotypes of dengue but not others. +
++“When we’re thinking about whether a vaccine is good, we think not only on the immediate protection that comes out on the first clinical trials, but also the longevity of this protection and how those immune responses are shaped over time as you get further and further away from that exposure,” said St. John. +
++One non-vaccine approach that has seen success is the World Mosquito Program’s initiative to breed virus-resistant mosquitoes. The bacterium Wolbachia prevents the Aedes mosquito from passing on dengue, yellow fever, chikungunya, and Zika virus. The World Mosquito Program breeds mosquitos that carry this naturally occurring bacteria and then release them into the natural environment. +
++“It’s exactly the same rationale for how vaccination works for humans. So you don’t need to vaccinate 100 percent of the people in the population to give protection to the whole population,” said O’Neill. “It’s effectively the same for our intervention … the bacteria that causes this effect has its own mechanism to transmit itself into the mosquito population.” +
++This initiative launched in Australia in 2011, and since then the country has reported no dengue transmission and the Wolbachia-positive mosquito population has become self-sustaining, said O’Neill. Additionally, this public health approach is cost-effective and socially acceptable. The initiative addresses multiple viruses at once, is self-sustaining, and does not create the same fear among those living in endemic areas as practices such as genetic engineering do, he added. +
++As the world turns its attention away from Covid, it’s important that scientists and policymakers continue to make progress — through vaccines and other more experimental methods — on long-existing diseases that continue to incapacitate and kill many people, especially the poor. And when it comes to dengue fever, vaccine manufacturers and public health leaders need to learn from past mistakes to ensure faith in these interventions does not wane. +
++“We should be using evidence to guide policy in the area of dengue control,” said O’Neill. “Any new intervention has to be able to show with the highest epidemiological evidence that their treatment or their innovation actually reduces disease before it can be heavily recommended.” +
+Is it possible to be truly original anymore — in your own life, in commerce, in art? +
++We’re in a cultural moment where it feels like so much is being rehashed, repackaged, and resold to a captive audience. This is certainly the case in entertainment, where the Hollywood reboot machine is the driving force behind what makes it to our screens; even “original” programming is frequently built from familiar storytelling tropes and formats. The same kind of recycling — sorry, remixing — holds true in pop music. +
++This carries over into matters of business and politics with just as much resonance. And when it comes to lifestyle topics like dieting, parenting, and even sex, we wind up circling the drain and repackaging old trends and ideas as hot new fads, too. +
++What makes newness, or novelty, or originality, so important in the first place, particularly in a society that heavily prioritizes individual comfort and choices? Are we in a uniquely not-new moment, or has it actually always felt this way? +
++Could we ever really tell a new story about a very old mermaid? +
++By Alissa Wilkinson +
++How today’s fight over pornography is rooted in a 40-year-old feminist schism. +
++By Constance Grady +
++The endless cycling — and recycling — of parenting advice. +
++By Anna North +
++When you democratize finance, you get the good and the bad. +
++By Emily Stewart +
++Self-improvement is old. What’s new is the bootstrapping mythos and toxic positivity of the very rich. +
++By Whizy Kim +
++CREDITS +
+
+Editors: Meredith Haggerty, Alanna Okun, Lavanya Ramanathan, Julia Rubin
Copy editors/fact-checkers: Elizabeth Crane, Kim Eggleston, Tanya Pai, Caitlin PenzeyMoog
Additional fact-checking: Anouck Dussaud, Matt Giles
Art direction: Dion Lee, Paige Vickers
Audience: Gabriela Fernandez, Shira Tarlo, Agnes Mazur
Production/project editors: Lauren Katz, Nathan Hall
+
Hockey | Indian women lose 2-4 to Australia in first Test - India’s goal scorers were Sangita Kumari (29th) and Sharmila Devi (40th)
Archery World Cup: India crash out of recurve team events - The women’s trio put up a sloppy show to make a first-round exit
IPL 2023, RR vs PBKS | Fate out of their own hands, Rajasthan Royals and Punjab Kings face desperate situation - Royals are better placed than Punjab Kings ahead of their final league game but both will have to rely on other results after an up and down season
Djokovic says new generation has arrived after Rome quarterfinal exit - Novak Djokovic, who lost to 20-year-old Dane Holger Rune in the Italian Open quarterfinals, said the next generation of players led by world number two Carlos Alcaraz is like a breath of fresh air for the sport.
Three out of four sexual assault charges against SL cricket Gunathilaka dropped - Gunathilaka was charged with four counts of sexual intercourse without consent for which the 32-year-old had been arrested by the Sydney police from the team hotel last November
Political parties in Tamil Nadu hail Supreme Court’s verdict upholding the law allowing jallikattu - The upshot of the ruling is that the State Assemblies can pass legislation on subjects placed on the Concurrent List, says Anbumani Ramadoss; Supreme Court has accepted the law passed by the State Cabinet, says K.S. Alagiri
BJP tried to manipulate civic polls in U.P. but didn’t succeed: Mayawati - Accusing the ruling party of misusing official machinery, the Bahujan Samaj Party leader said people did not allow the BJP’s plans to succeed
Why can’t Old City become New City? - Muslims should realise they are being used only as vote banks, says BJP Telangana president Bandi Sanjay Kumar
BJP makes a ‘BC Declaration’, to mobilise BCs to come to power in TS - Congress and Bharat Rashtra Samithi governments have only betrayed the interests of the BCs, says BJP BC Morcha national president K. Lakshman
Review of regulatory framework needed to create a vibrant real estate sector: study - Report by Gulati Institute of Finance and Taxation recommends reduction of stamp duty to 5%
Ukraine war: Russia launches ninth wave of missile attacks on Kyiv this month - All missiles over the capital were shot down, but falling debris caused some damage, Ukraine says.
Italy floods leave nine dead and force 13,000 from their homes - Almost every river flooded between the coast and the city of Bologna, leaving nine people dead.
Ukraine: The Mariupol steel workers longing for home - Mariupol’s former Azovstal workers yearn for their old lives in the now Russian-held city.
Italy floods: F1 Imola race cancelled as deadly deluge sparks evacuations in Emilia-Romagna - About 10,000 people flee their homes in Emilia-Romagna, with nine confirmed deaths across the region.
Ukraine conflict: Black Sea grain deal extended for two months - Russia allows exports of grain from Black Sea ports to continue, but criticises Western sanctions.
We’re effectively alone in the Universe, and that’s OK - Solitude is not a curse—it urges us to explore the mysteries of our galaxy and beyond. - link
What to expect from Sony’s May 24 not-E3 livestream - Spider-Man 2 and Final Fantasy XVI seem like givens—but what else will we see? - link
Elizabeth Holmes’ no good, very bad day: Bail denied and a bill for $452 million - Holmes will use the next 13 days to get her affairs in order, she told the court. - link
3D “digital twin” showcases wreck of Titanic in unprecedented detail - “This is a new phase for underwater forensic investigation and examination.” - link
Google’s new “inactive account” policy won’t delete years of YouTube videos - Google is going to wipe out old accounts, but not ones with YouTube videos? - link
A Russian wife turned to her husband and asked… -
++“What’s this special military operation our glorious leader keeps talking about?” +
++Her husband replied, “It’s a proxy war between Russia and NATO.” +
++“Oh, right. How’s it going?” +
++“Well,” he replied, “so far we’ve lost 200,000 soldiers, 4,000 tanks, 500 aircraft, numerous helicopters, loads of armoured vehicles and artillery pieces along with our ‘flag ship’.” +
++“Wow! What about NATO?” +
++“They haven’t turned up yet.” +
+ submitted by /u/Alpha-Studios
[link] [comments]
My girlfriend decided to surprise me, she dressed up as a policewoman and told me I was under arrest on suspicion of being good in bed. -
++After 2 minutes all charges were dropped due to a lack of evidence. +
+ submitted by /u/HelpingHandsUs
[link] [comments]
What has 4 letters, sometimes 9 letters, always 6 letters, but never has 5 letters. -
++Hint: Not a question +
+ submitted by /u/HelpingHandsUs
[link] [comments]
I dig, you dig, he dig, she dig, we dig, they dig. -
++It’s not a long poem,but it’s very deep. +
+ submitted by /u/iushdulal
[link] [comments]
What’s the difference between alzheimers and dementia? -
++What’s the difference between alzheimers and dementia? +
+ submitted by /u/whatwhatinthewhonow
[link] [comments]